Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives

There has been no improvement in outcome for patients with unresectable locally advanced (stage III) non–small cell lung cancer (NSCLC) for more than 10 years. The standard treatment for these patients is definitive concurrent chemotherapy and radiation (CCRT). Although the goal of treatment in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Hiroyuki, Okamoto, Isamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997215/
https://www.ncbi.nlm.nih.gov/pubmed/32099495
http://dx.doi.org/10.2147/LCTT.S184380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997215/
https://www.ncbi.nlm.nih.gov/pubmed/32099495
http://dx.doi.org/10.2147/LCTT.S184380

Ejemplares similares